Ji Xing buys Biogen’s acute ischemic stroke drug; Exelixis/BioInvent partnership ends; ClinChoice's deal in SEA
Ji Xing acquires Biogen’s experimental therapy for acute ischemic stroke: The Shanghai-based biopharma did not disclose the financial terms of the deal. Back in 2018, Biogen licensed the drug for $4 million upfront, with up to $335 million in milestones, before fully acquiring the asset in 2021. — Jaimy Lee
BioInvent gets back rights to immuno-oncology targets: Exelixis is returning the full rights to the Swedish biotech’s antibodies after announcing a restructuring earlier this week. BioInvent said the transition is expected to wrap up in the next 90 days. — Jaimy Lee
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
